Aptamer-based fluorescence polarization assay for separation-free exosome quantification

Quick Facts

• Publication title: Aptamer-based fluorescence polarization assay for separation-free exosome quantification
• Journal: Nanoscale
• Year: 2019
• DOI: 10.1039/c9nr01589b
• PMID/PMCID: 31089660

Research overview

Tumor-derived exosomes have emerged as promising cancer biomarkers and attracted increasing interest in non-invasive cancer diagnosis and treatment monitoring. However, the identification and quantification of exosomes in clinical samples such as blood remains challenging due to the difficulty in trade-off between recognition specificity and isolation efficiency.

Key findings

Tumor-derived exosomes have emerged as promising cancer biomarkers and attracted increasing interest in non-invasive cancer diagnosis and treatment monitoring.

However, the identification and quantification of exosomes in clinical samples such as blood remains challenging due to the difficulty in trade-off between recognition specificity and isolation efficiency.

Here we have developed an aptamer-based fluorescence polarization assay for exosome quantification, which is a separation-free, amplification-free and sensitive approach enabling direct quantification of exosomes in human plasma.

While the key specificity of this assay is based on the aptamer's inherent affinity to membrane proteins on exosomes, exosomes' inherent huge mass/volume acts as mass-based fluorescence polarization amplifier.

Echo Biotech Role

Echo Biotech's specific contribution should be verified from the full text or internal project record.

Related platforms: To Be Verified

Related services and capabilities: Co-authored Research

References

Original publication: Aptamer-based fluorescence polarization assay for separation-free exosome quantification Nanoscale. 2019. DOI: 10.1039/c9nr01589b. PMID/PMCID: 31089660.